Global Inosine Pranobex

Inosine Pranobex Comprehensive Study by Type (Tablet, Syrup), Application (Subacute Sclerosing Panencephalitis (SSPE), Herpes Simplex Virus (HSV), Varicella Infections, Human Papilloma Virus (HPV), Cytomegalovirus, Epstein–Barr Virus Infections, Acute Viral Respiratory Infections, Others), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2028

Inosine Pranobex Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Inosine Pranobex Market Overview:
Inosine pranobex (IP), commonly known as inosine acedoben dimepranol is a synthetic compound of the p-acetamido-benzoate salt of N–N dimethylamino-2-propanol with inosine. The drug was initially authorised in 1971 and is currently marketed in more than 70 countries worldwide for the treatment of viral diseases, including subacute sclerosing panencephalitis (SSPE), herpes simplex virus (HSV) and varicella infections, human papilloma virus (HPV), cytomegalovirus and Epstein–Barr virus infections, acute viral respiratory infections, measles, and immunosuppressed states. IP can impact both the humoral as well as the cell-mediated aspects of the immune system, in such a way that it enhances the host immune responses and can also exhibit antiviral effects.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Number of Elderly People and New Developments in Oral Vaccines

Market Growth Drivers:
Increase in Number of Patients Affected With Acute Disease, High Prevalence of Infectious Diseases and Rising Focus on Immunization Programs

Challenges:
Inadequate Access to Vaccines and Product Recalls

Restraints:
The High Cost of Vaccine Development

Opportunities:
Increasing Company Initiatives to Enhance Vaccine R&D and Growing Government Support for Vaccine Development

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Newport Pharmaceuticals (Ireland), Gedeon Richter (Hungary), Mochida (Japan), Sanofi (France), Andrómaco (Argentina), Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan), Alfasigma S.p.A. (Italy), Polfarmex (Poland), Sanfer (Mexico), Meprofarm (Indonesia), Novell Pharmaceutical (Indonesia) and Aflofarm (Poland). Analyst at AMA Research see European Players to retain maximum share of Global Inosine Pranobex market by 2028. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Inosine Pranobex market.

What Can be Explored with the Inosine Pranobex Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Inosine Pranobex Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Inosine Pranobex
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Inosine Pranobex market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Inosine Pranobex market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Inosine Pranobex, Suppliers of Inosine Pranobex, Wholesalers, Distributors and Retailers of Inosine Pranobex, Healthcare Industry, Pharmaceutical Manufacturers and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Tablet
  • Syrup
By Application
  • Subacute Sclerosing Panencephalitis (SSPE)
  • Herpes Simplex Virus (HSV)
  • Varicella Infections
  • Human Papilloma Virus (HPV)
  • Cytomegalovirus
  • Epstein–Barr Virus Infections
  • Acute Viral Respiratory Infections
  • Others
By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Number of Patients Affected With Acute Disease
      • 3.2.2. High Prevalence of Infectious Diseases
      • 3.2.3. Rising Focus on Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access to Vaccines
      • 3.3.2. Product Recalls
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Elderly People
      • 3.4.2. New Developments in Oral Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Inosine Pranobex, by Type, Application, Distribution Channel and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Inosine Pranobex (Value)
      • 5.2.1. Global Inosine Pranobex by: Type (Value)
        • 5.2.1.1. Tablet
        • 5.2.1.2. Syrup
      • 5.2.2. Global Inosine Pranobex by: Application (Value)
        • 5.2.2.1. Subacute Sclerosing Panencephalitis (SSPE)
        • 5.2.2.2. Herpes Simplex Virus (HSV)
        • 5.2.2.3. Varicella Infections
        • 5.2.2.4. Human Papilloma Virus (HPV)
        • 5.2.2.5. Cytomegalovirus
        • 5.2.2.6. Epstein–Barr Virus Infections
        • 5.2.2.7. Acute Viral Respiratory Infections
        • 5.2.2.8. Others
      • 5.2.3. Global Inosine Pranobex by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Inosine Pranobex Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Inosine Pranobex (Volume)
      • 5.3.1. Global Inosine Pranobex by: Type (Volume)
        • 5.3.1.1. Tablet
        • 5.3.1.2. Syrup
      • 5.3.2. Global Inosine Pranobex by: Application (Volume)
        • 5.3.2.1. Subacute Sclerosing Panencephalitis (SSPE)
        • 5.3.2.2. Herpes Simplex Virus (HSV)
        • 5.3.2.3. Varicella Infections
        • 5.3.2.4. Human Papilloma Virus (HPV)
        • 5.3.2.5. Cytomegalovirus
        • 5.3.2.6. Epstein–Barr Virus Infections
        • 5.3.2.7. Acute Viral Respiratory Infections
        • 5.3.2.8. Others
      • 5.3.3. Global Inosine Pranobex by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Inosine Pranobex Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Inosine Pranobex (Price)
      • 5.4.1. Global Inosine Pranobex by: Type (Price)
  • 6. Inosine Pranobex: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Newport Pharmaceuticals (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gedeon Richter (Hungary)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mochida (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Andrómaco (Argentina)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alfasigma S.p.A. (Italy)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Polfarmex (Poland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanfer (Mexico)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Meprofarm (Indonesia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novell Pharmaceutical (Indonesia)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Aflofarm (Poland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Inosine Pranobex Sale, by Type, Application, Distribution Channel and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Inosine Pranobex (Value)
      • 7.2.1. Global Inosine Pranobex by: Type (Value)
        • 7.2.1.1. Tablet
        • 7.2.1.2. Syrup
      • 7.2.2. Global Inosine Pranobex by: Application (Value)
        • 7.2.2.1. Subacute Sclerosing Panencephalitis (SSPE)
        • 7.2.2.2. Herpes Simplex Virus (HSV)
        • 7.2.2.3. Varicella Infections
        • 7.2.2.4. Human Papilloma Virus (HPV)
        • 7.2.2.5. Cytomegalovirus
        • 7.2.2.6. Epstein–Barr Virus Infections
        • 7.2.2.7. Acute Viral Respiratory Infections
        • 7.2.2.8. Others
      • 7.2.3. Global Inosine Pranobex by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Inosine Pranobex Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Inosine Pranobex (Volume)
      • 7.3.1. Global Inosine Pranobex by: Type (Volume)
        • 7.3.1.1. Tablet
        • 7.3.1.2. Syrup
      • 7.3.2. Global Inosine Pranobex by: Application (Volume)
        • 7.3.2.1. Subacute Sclerosing Panencephalitis (SSPE)
        • 7.3.2.2. Herpes Simplex Virus (HSV)
        • 7.3.2.3. Varicella Infections
        • 7.3.2.4. Human Papilloma Virus (HPV)
        • 7.3.2.5. Cytomegalovirus
        • 7.3.2.6. Epstein–Barr Virus Infections
        • 7.3.2.7. Acute Viral Respiratory Infections
        • 7.3.2.8. Others
      • 7.3.3. Global Inosine Pranobex by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Inosine Pranobex Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Inosine Pranobex (Price)
      • 7.4.1. Global Inosine Pranobex by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Inosine Pranobex: by Type(USD Million)
  • Table 2. Inosine Pranobex Tablet , by Region USD Million (2017-2022)
  • Table 3. Inosine Pranobex Syrup , by Region USD Million (2017-2022)
  • Table 4. Inosine Pranobex: by Application(USD Million)
  • Table 5. Inosine Pranobex Subacute Sclerosing Panencephalitis (SSPE) , by Region USD Million (2017-2022)
  • Table 6. Inosine Pranobex Herpes Simplex Virus (HSV) , by Region USD Million (2017-2022)
  • Table 7. Inosine Pranobex Varicella Infections , by Region USD Million (2017-2022)
  • Table 8. Inosine Pranobex Human Papilloma Virus (HPV) , by Region USD Million (2017-2022)
  • Table 9. Inosine Pranobex Cytomegalovirus , by Region USD Million (2017-2022)
  • Table 10. Inosine Pranobex Epstein–Barr Virus Infections , by Region USD Million (2017-2022)
  • Table 11. Inosine Pranobex Acute Viral Respiratory Infections , by Region USD Million (2017-2022)
  • Table 12. Inosine Pranobex Others , by Region USD Million (2017-2022)
  • Table 13. Inosine Pranobex: by Distribution Channel(USD Million)
  • Table 14. Inosine Pranobex Online , by Region USD Million (2017-2022)
  • Table 15. Inosine Pranobex Offline , by Region USD Million (2017-2022)
  • Table 16. South America Inosine Pranobex, by Country USD Million (2017-2022)
  • Table 17. South America Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 18. South America Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 19. South America Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 20. Brazil Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 21. Brazil Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 22. Brazil Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 23. Argentina Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 24. Argentina Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 25. Argentina Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 26. Rest of South America Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 29. Asia Pacific Inosine Pranobex, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 33. China Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 34. China Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 35. China Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 36. Japan Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 37. Japan Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 38. Japan Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 39. India Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 40. India Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 41. India Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 42. South Korea Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 43. South Korea Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 44. South Korea Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 45. Taiwan Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 46. Taiwan Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 47. Taiwan Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 48. Australia Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 49. Australia Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 50. Australia Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 54. Europe Inosine Pranobex, by Country USD Million (2017-2022)
  • Table 55. Europe Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 56. Europe Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 57. Europe Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 58. Germany Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 59. Germany Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 60. Germany Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 61. France Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 62. France Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 63. France Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 64. Italy Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 65. Italy Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 66. Italy Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 67. United Kingdom Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 70. Netherlands Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 71. Netherlands Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 72. Netherlands Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 73. Rest of Europe Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 76. MEA Inosine Pranobex, by Country USD Million (2017-2022)
  • Table 77. MEA Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 78. MEA Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 79. MEA Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 80. Middle East Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 81. Middle East Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 82. Middle East Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 83. Africa Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 84. Africa Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 85. Africa Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 86. North America Inosine Pranobex, by Country USD Million (2017-2022)
  • Table 87. North America Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 88. North America Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 89. North America Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 90. United States Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 91. United States Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 92. United States Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 93. Canada Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 94. Canada Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 95. Canada Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 96. Mexico Inosine Pranobex, by Type USD Million (2017-2022)
  • Table 97. Mexico Inosine Pranobex, by Application USD Million (2017-2022)
  • Table 98. Mexico Inosine Pranobex, by Distribution Channel USD Million (2017-2022)
  • Table 99. Inosine Pranobex Sales: by Type(K Tons)
  • Table 100. Inosine Pranobex Sales Tablet , by Region K Tons (2017-2022)
  • Table 101. Inosine Pranobex Sales Syrup , by Region K Tons (2017-2022)
  • Table 102. Inosine Pranobex Sales: by Application(K Tons)
  • Table 103. Inosine Pranobex Sales Subacute Sclerosing Panencephalitis (SSPE) , by Region K Tons (2017-2022)
  • Table 104. Inosine Pranobex Sales Herpes Simplex Virus (HSV) , by Region K Tons (2017-2022)
  • Table 105. Inosine Pranobex Sales Varicella Infections , by Region K Tons (2017-2022)
  • Table 106. Inosine Pranobex Sales Human Papilloma Virus (HPV) , by Region K Tons (2017-2022)
  • Table 107. Inosine Pranobex Sales Cytomegalovirus , by Region K Tons (2017-2022)
  • Table 108. Inosine Pranobex Sales Epstein–Barr Virus Infections , by Region K Tons (2017-2022)
  • Table 109. Inosine Pranobex Sales Acute Viral Respiratory Infections , by Region K Tons (2017-2022)
  • Table 110. Inosine Pranobex Sales Others , by Region K Tons (2017-2022)
  • Table 111. Inosine Pranobex Sales: by Distribution Channel(K Tons)
  • Table 112. Inosine Pranobex Sales Online , by Region K Tons (2017-2022)
  • Table 113. Inosine Pranobex Sales Offline , by Region K Tons (2017-2022)
  • Table 114. South America Inosine Pranobex Sales, by Country K Tons (2017-2022)
  • Table 115. South America Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 116. South America Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 117. South America Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 118. Brazil Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 119. Brazil Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 120. Brazil Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 121. Argentina Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 122. Argentina Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 123. Argentina Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 124. Rest of South America Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 125. Rest of South America Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 126. Rest of South America Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 127. Asia Pacific Inosine Pranobex Sales, by Country K Tons (2017-2022)
  • Table 128. Asia Pacific Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 129. Asia Pacific Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 130. Asia Pacific Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 131. China Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 132. China Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 133. China Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 134. Japan Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 135. Japan Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 136. Japan Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 137. India Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 138. India Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 139. India Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 140. South Korea Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 141. South Korea Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 142. South Korea Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 143. Taiwan Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 144. Taiwan Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 145. Taiwan Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 146. Australia Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 147. Australia Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 148. Australia Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 149. Rest of Asia-Pacific Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 150. Rest of Asia-Pacific Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 151. Rest of Asia-Pacific Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 152. Europe Inosine Pranobex Sales, by Country K Tons (2017-2022)
  • Table 153. Europe Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 154. Europe Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 155. Europe Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 156. Germany Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 157. Germany Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 158. Germany Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 159. France Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 160. France Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 161. France Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 162. Italy Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 163. Italy Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 164. Italy Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 165. United Kingdom Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 166. United Kingdom Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 167. United Kingdom Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 168. Netherlands Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 169. Netherlands Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 170. Netherlands Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 171. Rest of Europe Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 172. Rest of Europe Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 173. Rest of Europe Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 174. MEA Inosine Pranobex Sales, by Country K Tons (2017-2022)
  • Table 175. MEA Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 176. MEA Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 177. MEA Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 178. Middle East Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 179. Middle East Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 180. Middle East Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 181. Africa Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 182. Africa Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 183. Africa Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 184. North America Inosine Pranobex Sales, by Country K Tons (2017-2022)
  • Table 185. North America Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 186. North America Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 187. North America Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 188. United States Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 189. United States Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 190. United States Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 191. Canada Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 192. Canada Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 193. Canada Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 194. Mexico Inosine Pranobex Sales, by Type K Tons (2017-2022)
  • Table 195. Mexico Inosine Pranobex Sales, by Application K Tons (2017-2022)
  • Table 196. Mexico Inosine Pranobex Sales, by Distribution Channel K Tons (2017-2022)
  • Table 197. Inosine Pranobex: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Inosine Pranobex: by Type(USD Million)
  • Table 211. Inosine Pranobex Tablet , by Region USD Million (2023-2028)
  • Table 212. Inosine Pranobex Syrup , by Region USD Million (2023-2028)
  • Table 213. Inosine Pranobex: by Application(USD Million)
  • Table 214. Inosine Pranobex Subacute Sclerosing Panencephalitis (SSPE) , by Region USD Million (2023-2028)
  • Table 215. Inosine Pranobex Herpes Simplex Virus (HSV) , by Region USD Million (2023-2028)
  • Table 216. Inosine Pranobex Varicella Infections , by Region USD Million (2023-2028)
  • Table 217. Inosine Pranobex Human Papilloma Virus (HPV) , by Region USD Million (2023-2028)
  • Table 218. Inosine Pranobex Cytomegalovirus , by Region USD Million (2023-2028)
  • Table 219. Inosine Pranobex Epstein–Barr Virus Infections , by Region USD Million (2023-2028)
  • Table 220. Inosine Pranobex Acute Viral Respiratory Infections , by Region USD Million (2023-2028)
  • Table 221. Inosine Pranobex Others , by Region USD Million (2023-2028)
  • Table 222. Inosine Pranobex: by Distribution Channel(USD Million)
  • Table 223. Inosine Pranobex Online , by Region USD Million (2023-2028)
  • Table 224. Inosine Pranobex Offline , by Region USD Million (2023-2028)
  • Table 225. South America Inosine Pranobex, by Country USD Million (2023-2028)
  • Table 226. South America Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 227. South America Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 228. South America Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 229. Brazil Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 230. Brazil Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 231. Brazil Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 232. Argentina Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 233. Argentina Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 234. Argentina Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 235. Rest of South America Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 236. Rest of South America Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 237. Rest of South America Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 238. Asia Pacific Inosine Pranobex, by Country USD Million (2023-2028)
  • Table 239. Asia Pacific Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 240. Asia Pacific Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 241. Asia Pacific Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 242. China Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 243. China Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 244. China Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 245. Japan Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 246. Japan Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 247. Japan Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 248. India Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 249. India Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 250. India Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 251. South Korea Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 252. South Korea Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 253. South Korea Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 254. Taiwan Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 255. Taiwan Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 256. Taiwan Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 257. Australia Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 258. Australia Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 259. Australia Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 260. Rest of Asia-Pacific Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 261. Rest of Asia-Pacific Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 262. Rest of Asia-Pacific Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 263. Europe Inosine Pranobex, by Country USD Million (2023-2028)
  • Table 264. Europe Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 265. Europe Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 266. Europe Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 267. Germany Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 268. Germany Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 269. Germany Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 270. France Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 271. France Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 272. France Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 273. Italy Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 274. Italy Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 275. Italy Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 276. United Kingdom Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 277. United Kingdom Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 278. United Kingdom Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 279. Netherlands Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 280. Netherlands Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 281. Netherlands Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 282. Rest of Europe Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 283. Rest of Europe Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 284. Rest of Europe Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 285. MEA Inosine Pranobex, by Country USD Million (2023-2028)
  • Table 286. MEA Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 287. MEA Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 288. MEA Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 289. Middle East Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 290. Middle East Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 291. Middle East Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 292. Africa Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 293. Africa Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 294. Africa Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 295. North America Inosine Pranobex, by Country USD Million (2023-2028)
  • Table 296. North America Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 297. North America Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 298. North America Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 299. United States Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 300. United States Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 301. United States Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 302. Canada Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 303. Canada Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 304. Canada Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 305. Mexico Inosine Pranobex, by Type USD Million (2023-2028)
  • Table 306. Mexico Inosine Pranobex, by Application USD Million (2023-2028)
  • Table 307. Mexico Inosine Pranobex, by Distribution Channel USD Million (2023-2028)
  • Table 308. Inosine Pranobex Sales: by Type(K Tons)
  • Table 309. Inosine Pranobex Sales Tablet , by Region K Tons (2023-2028)
  • Table 310. Inosine Pranobex Sales Syrup , by Region K Tons (2023-2028)
  • Table 311. Inosine Pranobex Sales: by Application(K Tons)
  • Table 312. Inosine Pranobex Sales Subacute Sclerosing Panencephalitis (SSPE) , by Region K Tons (2023-2028)
  • Table 313. Inosine Pranobex Sales Herpes Simplex Virus (HSV) , by Region K Tons (2023-2028)
  • Table 314. Inosine Pranobex Sales Varicella Infections , by Region K Tons (2023-2028)
  • Table 315. Inosine Pranobex Sales Human Papilloma Virus (HPV) , by Region K Tons (2023-2028)
  • Table 316. Inosine Pranobex Sales Cytomegalovirus , by Region K Tons (2023-2028)
  • Table 317. Inosine Pranobex Sales Epstein–Barr Virus Infections , by Region K Tons (2023-2028)
  • Table 318. Inosine Pranobex Sales Acute Viral Respiratory Infections , by Region K Tons (2023-2028)
  • Table 319. Inosine Pranobex Sales Others , by Region K Tons (2023-2028)
  • Table 320. Inosine Pranobex Sales: by Distribution Channel(K Tons)
  • Table 321. Inosine Pranobex Sales Online , by Region K Tons (2023-2028)
  • Table 322. Inosine Pranobex Sales Offline , by Region K Tons (2023-2028)
  • Table 323. South America Inosine Pranobex Sales, by Country K Tons (2023-2028)
  • Table 324. South America Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 325. South America Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 326. South America Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 327. Brazil Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 328. Brazil Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 329. Brazil Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 330. Argentina Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 331. Argentina Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 332. Argentina Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 333. Rest of South America Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 334. Rest of South America Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 335. Rest of South America Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 336. Asia Pacific Inosine Pranobex Sales, by Country K Tons (2023-2028)
  • Table 337. Asia Pacific Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 338. Asia Pacific Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 339. Asia Pacific Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 340. China Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 341. China Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 342. China Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 343. Japan Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 344. Japan Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 345. Japan Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 346. India Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 347. India Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 348. India Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 349. South Korea Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 350. South Korea Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 351. South Korea Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 352. Taiwan Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 353. Taiwan Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 354. Taiwan Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 355. Australia Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 356. Australia Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 357. Australia Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 358. Rest of Asia-Pacific Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 359. Rest of Asia-Pacific Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 360. Rest of Asia-Pacific Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 361. Europe Inosine Pranobex Sales, by Country K Tons (2023-2028)
  • Table 362. Europe Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 363. Europe Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 364. Europe Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 365. Germany Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 366. Germany Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 367. Germany Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 368. France Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 369. France Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 370. France Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 371. Italy Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 372. Italy Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 373. Italy Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 374. United Kingdom Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 375. United Kingdom Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 376. United Kingdom Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 377. Netherlands Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 378. Netherlands Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 379. Netherlands Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 380. Rest of Europe Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 381. Rest of Europe Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 382. Rest of Europe Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 383. MEA Inosine Pranobex Sales, by Country K Tons (2023-2028)
  • Table 384. MEA Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 385. MEA Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 386. MEA Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 387. Middle East Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 388. Middle East Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 389. Middle East Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 390. Africa Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 391. Africa Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 392. Africa Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 393. North America Inosine Pranobex Sales, by Country K Tons (2023-2028)
  • Table 394. North America Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 395. North America Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 396. North America Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 397. United States Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 398. United States Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 399. United States Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 400. Canada Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 401. Canada Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 402. Canada Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 403. Mexico Inosine Pranobex Sales, by Type K Tons (2023-2028)
  • Table 404. Mexico Inosine Pranobex Sales, by Application K Tons (2023-2028)
  • Table 405. Mexico Inosine Pranobex Sales, by Distribution Channel K Tons (2023-2028)
  • Table 406. Inosine Pranobex: by Type(USD/Units)
  • Table 407. Research Programs/Design for This Report
  • Table 408. Key Data Information from Secondary Sources
  • Table 409. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Inosine Pranobex: by Type USD Million (2017-2022)
  • Figure 5. Global Inosine Pranobex: by Application USD Million (2017-2022)
  • Figure 6. Global Inosine Pranobex: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Inosine Pranobex Share (%), by Country
  • Figure 8. Asia Pacific Inosine Pranobex Share (%), by Country
  • Figure 9. Europe Inosine Pranobex Share (%), by Country
  • Figure 10. MEA Inosine Pranobex Share (%), by Country
  • Figure 11. North America Inosine Pranobex Share (%), by Country
  • Figure 12. Global Inosine Pranobex: by Type K Tons (2017-2022)
  • Figure 13. Global Inosine Pranobex: by Application K Tons (2017-2022)
  • Figure 14. Global Inosine Pranobex: by Distribution Channel K Tons (2017-2022)
  • Figure 15. South America Inosine Pranobex Share (%), by Country
  • Figure 16. Asia Pacific Inosine Pranobex Share (%), by Country
  • Figure 17. Europe Inosine Pranobex Share (%), by Country
  • Figure 18. MEA Inosine Pranobex Share (%), by Country
  • Figure 19. North America Inosine Pranobex Share (%), by Country
  • Figure 20. Global Inosine Pranobex: by Type USD/Units (2017-2022)
  • Figure 21. Global Inosine Pranobex share by Players 2022 (%)
  • Figure 22. Global Inosine Pranobex share by Players (Top 3) 2022(%)
  • Figure 23. Global Inosine Pranobex share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Newport Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Newport Pharmaceuticals (Ireland) Revenue: by Geography 2022
  • Figure 27. Gedeon Richter (Hungary) Revenue, Net Income and Gross profit
  • Figure 28. Gedeon Richter (Hungary) Revenue: by Geography 2022
  • Figure 29. Mochida (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Mochida (Japan) Revenue: by Geography 2022
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2022
  • Figure 33. Andrómaco (Argentina) Revenue, Net Income and Gross profit
  • Figure 34. Andrómaco (Argentina) Revenue: by Geography 2022
  • Figure 35. Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan) Revenue, Net Income and Gross profit
  • Figure 36. Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan) Revenue: by Geography 2022
  • Figure 37. Alfasigma S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 38. Alfasigma S.p.A. (Italy) Revenue: by Geography 2022
  • Figure 39. Polfarmex (Poland) Revenue, Net Income and Gross profit
  • Figure 40. Polfarmex (Poland) Revenue: by Geography 2022
  • Figure 41. Sanfer (Mexico) Revenue, Net Income and Gross profit
  • Figure 42. Sanfer (Mexico) Revenue: by Geography 2022
  • Figure 43. Meprofarm (Indonesia) Revenue, Net Income and Gross profit
  • Figure 44. Meprofarm (Indonesia) Revenue: by Geography 2022
  • Figure 45. Novell Pharmaceutical (Indonesia) Revenue, Net Income and Gross profit
  • Figure 46. Novell Pharmaceutical (Indonesia) Revenue: by Geography 2022
  • Figure 47. Aflofarm (Poland) Revenue, Net Income and Gross profit
  • Figure 48. Aflofarm (Poland) Revenue: by Geography 2022
  • Figure 49. Global Inosine Pranobex: by Type USD Million (2023-2028)
  • Figure 50. Global Inosine Pranobex: by Application USD Million (2023-2028)
  • Figure 51. Global Inosine Pranobex: by Distribution Channel USD Million (2023-2028)
  • Figure 52. South America Inosine Pranobex Share (%), by Country
  • Figure 53. Asia Pacific Inosine Pranobex Share (%), by Country
  • Figure 54. Europe Inosine Pranobex Share (%), by Country
  • Figure 55. MEA Inosine Pranobex Share (%), by Country
  • Figure 56. North America Inosine Pranobex Share (%), by Country
  • Figure 57. Global Inosine Pranobex: by Type K Tons (2023-2028)
  • Figure 58. Global Inosine Pranobex: by Application K Tons (2023-2028)
  • Figure 59. Global Inosine Pranobex: by Distribution Channel K Tons (2023-2028)
  • Figure 60. South America Inosine Pranobex Share (%), by Country
  • Figure 61. Asia Pacific Inosine Pranobex Share (%), by Country
  • Figure 62. Europe Inosine Pranobex Share (%), by Country
  • Figure 63. MEA Inosine Pranobex Share (%), by Country
  • Figure 64. North America Inosine Pranobex Share (%), by Country
  • Figure 65. Global Inosine Pranobex: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Newport Pharmaceuticals (Ireland)
  • Gedeon Richter (Hungary)
  • Mochida (Japan)
  • Sanofi (France)
  • Andrómaco (Argentina)
  • Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan)
  • Alfasigma S.p.A. (Italy)
  • Polfarmex (Poland)
  • Sanfer (Mexico)
  • Meprofarm (Indonesia)
  • Novell Pharmaceutical (Indonesia)
  • Aflofarm (Poland)
Select User Access Type

Key Highlights of Report


Apr 2023 218 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Inosine Pranobex Quantitative research analysis
Global Inosine Pranobex Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Inosine Pranobex market are Newport Pharmaceuticals (Ireland), Gedeon Richter (Hungary), Mochida (Japan), Sanofi (France), Andrómaco (Argentina), Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan), Alfasigma S.p.A. (Italy), Polfarmex (Poland), Sanfer (Mexico), Meprofarm (Indonesia), Novell Pharmaceutical (Indonesia) and Aflofarm (Poland), to name a few.
"Increasing Number of Elderly People " is seen as one of major influencing trends for Inosine Pranobex Market during projected period 2022-2028.
Tablet segment in Global market to hold robust market share owing to "Increase in Number of Patients Affected With Acute Disease ".

Know More About Global Inosine Pranobex Report?

Have a Query? Click Here

Other Related Reports

Methadone Hydrochloride Comprehensive Study by Type (Methadone Hydrochloride Tablet, Methadone Hydrochloride Oral), Application (Adults, Children), End Use (Hospitals, Medical Research Center, Pharma...
$ 3350
Gastroparesis Drugs Comprehensive Study by Type (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injection, Other), Application (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical ...
$ 3750
Octreotide Acetate Comprehensive Study by Type (Immediate-release Injection Form, LAR Depot Form), Application (Medical Therapeutic, Medical Prophylactic), Form (Injectable, Tablets, Capsules, Others...
$ 3350
Vasodilators Comprehensive Study by Type (Arterial Dilators, Venous Dilators, Mixed Dilators), Application (Hypertension, Angina, Heart Failure), Drug Type (Hydralazine, ACE inhibitors, Minoxidil), D...
$ 3650
Cell Isolation/Cell Separation Comprehensive Study by Type (Reagent, Instrument, Others), Application (Biomolecule Isolation, Cancer Research, Stem Cell Research, Tissue Regeneration & Regenerative M...
$ 3750
Psoriasis Treatment Comprehensive Study by Type (Psoriatic Arthritis, Plaque Psoriasis, Others), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Online...
$ 3800